Skip to Main Content

Paper Details

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.
Kidney Int Rep
78
2017
Author NameAffiliation
James A TumlinUniversity of Tennessee College of Medicine
  • 1 - 1

Datasets

Release 1.2